Replimune Group Inc. (NASDAQ: REPL) stock jumped 1.00% on Thursday to $19.21 against a previous-day closing price of $19.02. With 0.61 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.6 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $19.32 whereas the lowest price it dropped to was $18.59. The 52-week range on REPL shows that it touched its highest point at $29.52 and its lowest point at $13.54 during that stretch. It currently has a 1-year price target of $52.00. Beta for the stock currently stands at 1.62.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of REPL was down-trending over the past week, with a drop of -2.19%, but this was up by 15.03% over a month. Three-month performance dropped to -2.98% while six-month performance fell -3.18%. The stock gained 35.86% in the past year, while it has lost -29.38% so far this year. A look at the trailing 12-month EPS for REPL yields -2.86 with Next year EPS estimates of -3.66. For the next quarter, that number is -0.82. This implies an EPS growth rate of -32.40% for this year and -16.60% for next year.
Float and Shares Shorts:
At present, 66.00 million REPL shares are outstanding with a float of 45.27 million shares on hand for trading. On Apr 27, 2023, short shares totaled 6.91 million, which was 12.21% higher than short shares on Mar 30, 2023. In addition to Mr. Philip Astley-Sparke F.S.A., FSA as the firm’s CEO & Director, Dr. Robert Coffin Ph.D. serves as its Founder, Pres, Chief R&D Officer and Director.
Through their ownership of 87.32% of REPL’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 47.75% of REPL, in contrast to 38.97% held by mutual funds. Shares owned by individuals account for 37.04%. As the largest shareholder in REPL with 9.70% of the stake, T. Rowe Price Associates, Inc. holds 5,495,616 shares worth 5,495,616. A second-largest stockholder of REPL, Baker Bros. Advisors LP, holds 4,578,280 shares, controlling over 8.08% of the firm’s shares. Redmile Group LLC is the third largest shareholder in REPL, holding 3,811,988 shares or 6.73% stake. With a 4.20% stake in REPL, the T Rowe Price New Horizons Fund is the largest stakeholder. A total of 2,377,770 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 3.30% of REPL stock, is the second-largest Mutual Fund holder. It holds 1,866,960 shares valued at 31.23 million. T Rowe Price Health Sciences Fund holds 2.60% of the stake in REPL, owning 1,475,437 shares worth 24.68 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, REPL reported revenue of $0.00 and operating income of -$40.02M. The EBITDA in the recently reported quarter was -$41.42M and diluted EPS was -$0.78.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for REPL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With REPL analysts setting a high price target of $70.00 and a low target of $33.00, the average target price over the next 12 months is $50.67. Based on these targets, REPL could surge 264.39% to reach the target high and rise by 71.79% to reach the target low. Reaching the average price target will result in a growth of 163.77% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded REPL stock several times over the past three months with 8 Buys and 0 Sells. In these transactions, 442,100 shares were bought while 0 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 474,600 while 15,000 shares were sold.